Departments of Medicine, Hematology and Oncology, Ellis Fischel Cancer Center, University of Missouri, 15 Business Loop 70 West, DC 116.71 Columbia, MO 65203, USA.
Heart Fail Clin. 2011 Jul;7(3):373-84. doi: 10.1016/j.hfc.2011.03.008. Epub 2011 May 20.
Although the use of chemotherapy and targeted therapy has improved the clinical benefit, progression-free survival, and overall survival of various cancers in recent years, old and new toxicities have limited their use. To balance the risk with the benefit of treatment, Common Toxicity Criteria and now Common Terminology Criteria for Adverse Events (CTCAE) have been used by the oncology community for more than 20 years to assess toxicity from cancer treatment. This article details the description and grading of cardiac toxicities reported in association with cancer treatment and the use of CTCAE to assess them.
尽管近年来化疗和靶向治疗的应用提高了各种癌症的临床获益、无进展生存期和总生存期，但新老毒性限制了它们的应用。为了平衡治疗风险与获益，肿瘤学界 20 多年来一直使用通用毒性标准和现在的不良事件通用术语标准（CTCAE）来评估癌症治疗的毒性。本文详细描述了与癌症治疗相关的心脏毒性的描述和分级，并介绍了如何使用 CTCAE 进行评估。
